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Abstract
Background: Epigenetic reading domains are involved in the regulation of gene expression and chromatin state
by interacting with histones in a post-translational modification specific manner. A detailed knowledge of the
target modifications of reading domains, including enhancing and inhibiting secondary modifications, will lead to a
better understanding of the biological signaling processes mediated by reading domains.
Results: We describe the application of Celluspots peptide arrays which contain 384 histone peptides carrying 59
post translational modifications in different combinations as an inexpensive, reliable and fast method for initial
screening for specific interactions of reading domains with modified histone peptides. To validate the method, we
tested the binding specificities of seven known epigenetic reading domains on Celluspots peptide arrays, viz. the
HP1ß and MPP8 Chromo domains, JMJD2A and 53BP1 Tudor domains, Dnmt3a PWWP domain, Rag2 PHD domain
and BRD2 Bromo domain. In general, the binding results agreed with literature data with respect to the primary
specificity of the reading domains, but in almost all cases we obtained additional new information concerning the
influence of secondary modifications surrounding the target modification.
Conclusions: We conclude that Celluspots peptide arrays are powerful screening tools for studying the specificity
of putative reading domains binding to modified histone peptides.
Background
Epigenetic signals include the methylation of DNA, the
post-translational modification (PTM) of the N-terminal
histone tails and non-coding RNAs. In eukaryotes, these
epigenetic marks are involved in the regulation of gene
expression and chromatin state. The most studied his-
tone tail modifications are acetylation of Lys, methyla-
tion of Lys or Arg leading to mono-, di- (symmetric or
asymmetric in the case of Arg) or trimethylation in the
case of Lys and phosphorylation at Ser or Thr [1-4].
These PTMs are recognized and bound by specific read-
ing domains which mediate most of the biological func-
tions of histone tail PTMs [5,6]. Up to date more than
100 different PTMs have been discovered in histone
tails, with many of them known to have distinct and
important roles in the regulation of gene expression,
DNA repair and replication, chromatin biology and the
cell cycle. While histone lysine acetylation has a general
activating role on transcription, histone lysine methyla-
tion can function both as an activating or a repressing
mark depending on the site of methylation and the
number of methyl groups added.
Acetylated histones are recognized by Bromo domains,
an about 110 amino acid residues long domain folded
into a left-handed four a-helical bundle. The family of
Bromo domains has more than 70 identified members
which are found in many chromatin-associated factors,
including histone acetyltransferases or chromatin-remo-
deling factors. The Bromo domain containing protein 2
(BRD2) belongs to the Bromo Domain And Extra-Term-
inal Domain (BET) family, members of which contain
two Bromo domains and an additional conserved term-
inal domain. It was reported that the tandem Bromo
domains of BRD2 bind to H4K12ac [7].
Protein domains belonging to the Royal family include
among others Tudor, Chromo and MBT domains. They
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The Chromatin Organization Modifier (Chromo)
domain is about 50 amino acids in size which are folded
into a small ß-finger flanked by one a-helix. The
Chromo domain family consists of more than 120 iden-
tified members. The Chromo domain of the Hetero-
chromatin protein 1 beta (HP1ß) binds specifically to
H3K9me3 and with weaker affinity to H3K9me2 and it
is involved in the establishment of heterochromatin
[8,9]. Another example of a Chromo domain containing
protein, though less characterized, is the M-phase phos-
phoprotein 8 (MPP8), which has been shown to recog-
nize H3K9me3, but also H3K9me1 and H3K9me2
[10-13].
The Tudor domain folds into a ß-sandwich flanked by
one a-helix. Members of this domain family are for
example the p53 binding protein 1 (53BP1), which has
been shown to interact with H4K20me2 [14,15] and
H3K79me2 [16], and the Jumonji domain containing
protein 2A (JMJD2A) reported to bind to H4K20me3,
H4K20me2, H3K4me3, H3K4me2 and H3K9me3
[14,17,18].
However, a specific interaction with modified amino
acids is possible in other families as well. For example,
the PWWP domain (Proline Tryptophan Tryptophan
Proline Motif) present in DNA methyltransferase 3a was
shown to read H3K36me3 [19] and the Plant Homeodo-
main (PHD) fingers, which are found in more than 100
proteins, interact with methylated lysine residues. These
binding modules are about 50 amino acids long and
contain two binding sites for zinc ions. The PHD finger
of Rag2, an essential component of the Rag1/2 V(D)J
recombinase, which mediates antigen-receptor gene
assembly, interacts with H3K4me3 [20].
The investigation of the PTM specific binding of read-
ing domains to peptides requires testing of binding to as
many peptides with different PTMs as possible which is
impeded by the high costs of synthetic modified pep-
tides. Recently, we described the application of Cellu-
spots peptide arrays for the quality assessment of
commercial antibodies [21]. Peptide synthesis on cellu-
lose membranes by the SPOT method allows the gen-
eration of many peptides with variable sequence and
modifications at reasonable costs [22,23]. Peptide SPOT
arrays are valuable tools for the analysis of the specifi-
city of peptide modifying enzymes [24-28] or the bind-
ing specificity of antibodies and reading domains
[19,21,22,26,28-32]. In the Celluspots technique, pep-
tides are synthesized following the conventional SPOT
synthesis on a cellulose matrix, but after the synthesis
the cellulose piece together with the peptides is solubi-
lized and spotted on glass slides [33]. Consequently, Cel-
luspots peptide arrays are less expensive, because many
arrays can be produced from one synthesis and, due to
the fact that they are smaller, the assay can be per-
formed with much less reagent.
Results
In the present study, the binding specificities of seven
known reading domains were analyzed using Celluspots
peptide arrays comprising 384 peptides from 8 different
regions of the N-terminal histone tails, viz. H3 1-19, 7-
26, 16-35 and 26-45, H4 1-19 and 11-30, H2A 1-19 and
H2B 1-19. The arrays are commercially available from
Active Motif and feature 59 post-translational modifica-
tions (most of them identified, some of them hypotheti-
cal) in many different combinations (Additional file 1).
Binding of the GST fused reading domain proteins to
peptide arrays was visualized using an anti-GST anti-
body, followed by a secondary anti-goat-HRP antibody
and ECL detection system. The domains were selected
to represent the different folds of reading domains and
show a wide range of specificities. Control experiments
showed that GST alone did not give rise to any signal
on the peptide array (data not shown). Each reading
domain was tested at least two times on the peptide
arrays to ensure that the results are reliable. In case of
weak signals, the experiment was repeated with higher
protein concentration. In case of an overexposed image,
the protein concentration was reduced. For quality con-
trol, each glass slide contains two identical copies of the
array. The binding intensities for each tested reading
domain were analyzed with the Array Analyze program,
which calculates the average of the binding intensities to
corresponding peptide spots in both copies of the array
and prepares a graphical output - one scatter plot illus-
trating the binding intensities observed at corresponding
spots in both copies of the array and a bar diagram
showing the distribution of deviations of the binding
intensities to the corresponding spots. For all arrays, the
main error range of the two internal duplicates was
between 0 and 5% indicating that binding of reading
domains to the arrays was reproducible.
Peptide binding of the HP1ß Chromo domain
The HP1ß Chromo domain is known to recognize
H3K9me3 and to a lower degree H3K9me2 [8,9]. We
tested HP1ß full length protein binding to the modified
histone tail peptides on Celluspots peptide arrays (Figure
1A) and observed the expected specificity towards
H3K9me3/2, with a clear preference for H3K9me3. One
big advantage of the Celluspots histone tail peptide
arrays is that there are up to 4 different modifications
on one peptide giving rise to the detailed specificity ana-
lysis of enhancing or inhibiting secondary modifications.
On the array it was very clear that H3S10ph prevented
binding of HP1ß to H3K9me3/2 (Figure 1A). This result
is in agreement with literature, because S10P has been
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Page 2 of 12Figure 1 Analysis of the binding specificity of Chromo domains on Celluspots peptide arrays. A) Binding analysis of HP1ß. The upper part
of each array analysis shows the image of the array. Peptide spots are annotated on the left copy of the duplicates. The color code is described
on the right side of the image. The red arrows indicate unbound peptide spots carrying the target modifications and secondary inhibiting
modifications, which are specified on the right side of the image. In the lower part of the figure, a scatter plot of the binding intensities to
corresponding peptides on both identical copies of the array and a bar diagram indicating the range of deviations is shown. B) Binding analysis
of the MPP8 Chromo domain. For a description of the figure see legend of panel A.
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Page 3 of 12shown previously to prevent binding of HP1ß to H3
peptides and it has been found to release it from
H3K9me3 modified chromatin in vivo [34]. Additionally
we found that H3R8Citr and H3T11ph also inhibited
binding of H3K9me2/3 peptides and H3R8me2s reduced
binding of H3K9me2, which to our knowledge has not
been reported so far. Secondary modifications like
H3R8me2a/s, H3K14ac, H3R2me2a, H3K4me1/2/3 or
H3K4ac had no or only a mild effect on HP1ß binding
to H3K9me3/2.
In the structure of HP1ß bound to the H3K9me3 pep-
tide (pdb entry 1KNE) [35] (Figure 2), E23 is the only
residue that closely approaches R8. To study the role of
E23 in R8 recognition, we generated and purified the
E23A variant and studied its peptide interaction on Cel-
luspots arrays. As shown in Figure 3, there was no gen-
eral change in specificity. However several spots
containing H3K9me2 combined with R8me2s, which
were not bound by wild type HP1ß, were bound by the
E23A variant indicating that the inhibitory effect of
R8me2s was alleviated in the E23A variant. This result
illustrates the application of Celluspots arrays in the
specificity analysis of variants of reading domains.
Peptide binding of the MPP8 Chromo domain
Next we studied the binding specificity of the MPP8
Chromo domain on Celluspots peptide arrays. The
structures of the Chromo domains of HP1ß and MPP8
are similar [13] and their specificity is analogous,
because the MPP8 Chromo domain is known to prefer-
entially interact with H3K9me3, weaker with H3K9me2
and to a lesser extent with H3K9me1, but not with
H3K27me3 or me2 [10-13]. On the Celluspots arrays, by
far the strongest signal was observed for H3K9me3
modified peptides (Figure 1B). The secondary modifica-
tions H3R8me2a/s, H3K14ac, H3R2me2s/a, H3K4me1/
2/3 or H3K4ac had very weak or no influence on pep-
tide binding. The signal intensity for H3K9me2 binding
was weak in comparison with H3K9me3, and binding to
H3K9me1 only occurred if some secondary modifica-
tions were present on the peptides. As observed for
HP1ß, H3S10ph or H3T11ph inhibited peptide binding.
However, H3R8Citr which inhibited binding of HP1ß to
H3K9me3 did not reduce binding of MPP8. In contrast
to the previous studies, we observed weak binding to
H3K27me3/2 as well, which was disrupted when the
adjacent H3S28 was phosphorylated. Loss of binding of
the H3K9me3-S10ph double modified peptide was con-
firmed by fluorescence depolarization measurement
using purified peptides (Figure 4).
Peptide binding of the JMJD2A double Tudor domain
The double Tudor domain of JMJD2A was reported to
interact preferentially with H4K20me3 and H4K20me2
and with weaker affinity with H3K4me3 and H3K4me2
[ 1 4 , 1 7 ] .A d d i t i o n a l l y ,i tw a ss h o w nt h a ti tb i n d s
H3K9me3 with very weak affinity, which was only seen
in a peptide pull-down experiment, but not on a protein
microarray done in the same study [14]. On the Cellu-
spots arrays, the strongest binding signal was observed
for H4K20me3 modified peptides (Figure 5A). While the
secondary modifications H4K12ac and H4K16ac had no
effect on the signal intensity, asymmetric or symmetric
methylation of the adjacent arginine 19 reduced binding
severely. A less prominent signal reduction was observed
for H4R24me2a/s as well. Following H4K20me3,
H4K20me2 was the next best bound modification on
the peptide array with similar effects concerning the
Figure 2 Superposition of the HP1ß (pdb entry 1KNE)( d a r k
green) and MPP8 Chromo domains (pdb entry 3QO2) (red) in
complex with H3K9me3 peptides (light green for HP1 and
orange for MPP8). 232 backbone atoms of both domains were
superimposed with a root mean square of 0.92 Å using Deep View
Swiss PDB viewer 3.7. The distance between the closest atoms of
E23 of HP1 and R8 of the peptide is 5.14 Å. In MPP8, E97
approaches R8 more closely, with a distance of only 2.41 Å between
the closest atoms.
Figure 3 B i n d i n go fw i l dt y p eH P 1 ßa n di t sE 2 3 Av a r i a n tt o
Celluspots arrays showing similar binding specificity.
Highlighted are some of the spots which carry H3K9me2 and
H3R8me2s, some of them together with other modifications. The
E23A variant binds better to these spots indicating that the
negative effect of H3R8me2s on binding of H3K9me2 is reduced by
the E23A mutation.
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24. The binding to a single modified H3K4me3 was very
weak (Figure 5A, spot No. 1) or in the case of
H3K4me2 and H3K9me3 not detectable. However, we
observed good binding (although weaker than to
H4K20me3) to some peptides containing both
H3K4me3 and H3K9me3 or H3K9me2 (Figure 5A, spots
No. 2-5). While H3R8me2a/s did not influence binding
of the double Tudor domain to these modified peptides,
H3R2me2a/s abolished bindin g .F i n a l l y ,w eo b s e r v e d
H3K27me3 binding by the double Tudor domain, which
has not been reported so far. The binding signal for
H3K27me3 was comparable with the intensity for
H4K20me2. Phosphorylation of H3S28 as a secondary
modification prevented binding of the double Tudor
domain to H3K27me3. Former studies on the interac-
tion of the JMJD2A double Tudor domain with modi-
fied histone tails did not include H3K27me3 [14],
therefore this interaction should be validated by addi-
tional experiments.
Peptide binding of the 53BP1 tandem Tudor domain
In the past, some histone modifications were reported to
interact with the tandem Tudor domain of 53BP1:
H3K79me2 [16], a modification which is not present on
the Celluspots peptide array, and H4K20me2,
H4K20me1, H3K4me2 and H3K9me2 [14,15]. Indeed,
all H4K20me2 modified peptides (the main target
reported for the tandem Tudor domain of 53BP1 [14])
were specifically recognized by the 53BP1 tandem
Tudor domain on the peptide array (Figure 5B). Inter-
estingly, the secondary modifications H4K16ac,
H4K12ac and, to a lesser degree, H4R24me2a enhanced
the binding affinity of the tandem Tudor domain for
H4K20me2, since the peptides carrying H4K20me2
combined with those modifications showed the stron-
gest binding. The other reported interactions with
H4K20me1, H3K4me2 and H3K9me2 [14] were not
observed on the peptide array.
Peptide binding of the Dnmt3a PWWP domain
Another reading domain which was tested on the Cellu-
spots peptide arrays is the PWWP domain of Dnmt3a.
We observed previously a specific interaction of the
Dnmt3a PWWP domain with H3K36me3 on SPOT
arrays, which was confirmed in follow-up experiments
[19]. In agreement with this finding, the PWWP domain
specifically bound to H3K36me3 modified peptides on
Celluspots arrays as well (Figure 6A). Since there is only
one H3K36me3-modified peptide spot, the effect of
enhancing or inhibiting secondary modifications could
not be studied in this case. Except for H3K36me2,
which gave rise to a weaker binding signal in compari-
s o nt oH 3 K 3 6 m e 3 ,t h e r ew e r en oo t h e rm o d i f i c a t i o n s
recognized by the Dnmt3a PWWP domain on the pep-
tide array, showing a high specificity for methylated
H3K36.
Peptide binding of the Rag2 PHD finger
Out of the group of H3K4me3 interacting PHD finger
binding modules, we selected the PHD finger of Rag2
for this study which has been reported to interact with
H3K4me3 [20]. As expected, the strongest signal was
observed for H3K4me3 modified peptides on the Cellu-
spots arrays (Figure 6B). In comparison to H3K4me3,
the signal intensity of bound H3K4me2 was greatly
reduced and there was almost no binding signal
observed for H3K4me1 modified peptides. In concert
with literature, we found that the PHD finger of Rag2 is
highly specific for H3K4me3, because there were no
other modified amino acid residues targeted on the pep-
tide array. The secondary modification H3T3ph comple-
tely abolished the binding of Rag2 PHD finger to
H3K4me3-modified peptides.
Peptide binding of the BRD2 Bromo domain
The Bromo domain protein BRD2 had been shown to
interact with H4K12ac-modified chromatin [7] and the
second Bromo domain of BRD2 was found to recognize
H4K5K12-diacetylated peptides [36,37]. Therefore, we
tested the second Bromo domain of BRD2 on Celluspots
peptide arrays and found that it bound preferentially to
tri- or tetra-acetylated peptides from histone H4 (Figure
Figure 4 Binding of the MPP8 Chromo domain to H3K9me3
(red) and H3K9me3-S10ph peptides (green) analyzed in
solution by fluorescence depolarization. Binding constants were
determined by fitting of the data to a binary binding equilibrium to
be 0.12 μM for H3K9me3 similarly as observed recently by
isothermal calorimetry [13] and > 50 μM for H3K9me3-S10ph.
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Page 5 of 126C) with some preference for H4K5acK12ac. The tetraa-
cetylated peptide H4K5ac-K8ac-K12ac-K16ac showed
the strongest binding signal. The hypothetical modifica-
tion H4K20ac is included on the peptide array and the
triacetylated H4K12ac-K16ac-K20ac peptide was recog-
nized by the Bromo domain with similar affinity as the
other triacetylated H4 peptides. Notably the monoacety-
lated peptides H4K5ac, H4K8ac, H4K12ac and H4K16ac
Figure 5 Analysis of the binding specificity of the JMJD2A double Tudor (A) and 53BP1 tandem Tudor (B) domains on Celluspots
peptide arrays. For a description of the figure see the legend of figure 1A.
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Page 6 of 12were not bound and diacetylated peptides containing
H4K5ac-K8ac were only weakly bound. This is not sur-
prising, since it was shown in the past that some Bromo
domains preferentially bind to multiple acetylated his-
tone tails [38].
Discussion
Reading domains mediate PTM specific protein/protein
interactions, in the case of epigenetic reading domains, a
PTM specific interaction with histone peptides occurs.
These protein domains are essential players in
Figure 6 Analysis of the binding specificity of the Dnmt3a PWWP domain (A), the Rag2 PHD finger (B) and the BRD2 second Bromo
domain (C) on Celluspots peptide arrays. For a description of the figure see legend of figure 1A.
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Page 7 of 12epigenetic signaling, because they translate the specific
PTM patterns of histones into a biological function.
Identification and study of reading domains includes the
analysis of their specificity with respect to the primary
PTM recognized, the peptide sequence and the influ-
ence of additional secondary PTMs nearby. One exam-
ple for a screening system for the identification of PTM
binding proteins is a protein microarray used by Kim et
al. in 2006. For that study domains of known chroma-
tin-associated proteins were cloned as GST fusions and
spotted onto nitrocellulose-coated glass slides and incu-
bated with fluorophore-labeled N-terminal histone H3
and H4 peptides carrying different modifications [14].
Peptide arrays have been used as an alternative screen-
ing tool as well. Bua et al. applied peptide arrays con-
taining biotinylated histone peptides, which were either
unmodified or carried a single modification at known
PTM sites [10], later larger peptide arrays also contain-
ing combinations of PTMs were used [21,31,39,40]. We
applied Celluspots arrays for the screening of antibody
binding to modified histone tails [21], because they
allow for a cost effective presentation of many potential
targets with different modification patterns.
Recently, we also used Celluspots peptide arrays for
the initial screening of the binding specificity of two
PHD finger like domains - the ADD domains of ATRX
and Dnmt3a [31,40]. The ADD domain of Dnmt3a was
reported to bind to unmodified H3K4 and the structure
of this complex had been solved [41]. On the peptide
array, the Dnmt3a ADD domain interacted only with
peptides where H3K4 is either unmodified or mono-
methylated, but not when it is di- or trimethylated [31].
While secondary modifications like H3R2me2a/s had no
or only a mild effect on the binding affinity, H3T3P,
H3S10ph and H3T11ph prevented binding of the
Dnmt3a ADD domain. We have shown that the ATRX
ADD domain binds to H3K9me3 in the absence of
H3K4me2/3 on the peptide array [40] and confirmed
this result using purified peptides. Later, additional
experiments confirmed this finding [42,43].
Here, we tested the binding of several reading
domains to Celluspots peptide arrays and show that the
binding specificities observed with Celluspots arrays in
general agree nicely with literature results. One of the
big advantages of this approach is that many different
modified peptides are presented on the array such that
no initial hypothesis on the binding motif is necessary.
In addition, peptides with up to four combined modifi-
cations are present, which allows for analysis of combi-
natorial readout to identify secondary modifications
which enhance or reduce the binding affinity to peptides
which carry the primary target modification.
An inhibiting effect of some secondary modifications
was seen for most of the studied reading domains. For
example, HP1ß binding to H3K9me3 was prevented by
H3R8Citr, H3S10ph and H3T11ph. All of these modi-
fied amino acids are either close or adjacent to the tar-
get trimethyl lysine, but an additional modification at an
adjacent residue does not necessarily influence binding
as seen in the case of the MPP8 Chromo domain. Even
though binding was inhibited by H3S10ph and
H3T11ph similarly as for HP1ß, H3R8Citr did not have
any effect on MPP8 Chromo domain binding to
H3K9me3. Trying to understand that difference, we
superimposed the structures of HP1ß (pdb entry 1KNE)
[35] and MPP8 Chromo domain (pdb entry 3QO2) [13]
in complex with H3K9me3 peptides and compared the
distances of unmodified R8 in the peptides to the near-
est side chain atoms of the Chromo domains, which are
E23 in HP1ß and E97 in MPP8 (Figure 2). In MPP8, the
distance between the E97 side chain atoms and R8 is
2.41 Å indicative of a strong hydrogen bond being
formed, that also would be present after citrullination of
the arginine. In contrast, in HP1ß the nearest side chain
to R8 is E23 with a distance of 5.14 Å, which may pro-
vide some electrostatic interaction but does not support
a hydrogen bond. The electrostatic contact between E23
and R8 would be lost after citrullination, because citrul-
lination of arginine removes its charge which may
explain why citrullination of H3R8 prevents binding of
HP1ß but not of MPP8.
We observed with several domains that the presence
of one or more additional modifications improved bind-
ing to peptides which carried the primary mark. This
effect could be due to technical problems like unequal
peptide synthesis or surface binding. It could also mean
that these combinations of PTMs are biologically impor-
tant, like in the case of HP1ß only binding to H3K9me3
if S10 is not phosphorylated [34] or the ATRX ADD
domain only binding to H3K9me3 if K4 is unmethylated
[40]. Furthermore, one may also speculate that improved
binding by the presence of additional PTMs may indi-
cate that the amino acid sequence of the peptides used
is not ideal for binding of that reading domain, which
would suggest binding to other modified non-histone
proteins. Therefore, the biological relevance of enhan-
cing or inhibiting secondary modifications found in an
initial screening for specific interactions of a reading
domain with modified peptides needs to be further
investigated with additional experiments. In the case of
HP1ß, for example, it has been shown that phosphoryla-
tion of H3S10 during the M-phase of the cell cycle leads
to the release of HP1 proteins from H3K9me3 modified
chromatin [34] such that this detail of the array results
has a biological meaning.
Another example of the inhibition of binding by a sec-
ondary modification was seen with the JMJD2A double
Tudor domain binding to H4K20me3. While H4K12ac
Bock et al. BMC Biochemistry 2011, 12:48
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Page 8 of 12and H4K16ac had no effect on the signal intensity, we
observed that asymmetric or symmetric methylation of
the arginine 19 reduced binding of the JMJD2A double
Tudor domain to H4K20me3 severely. This observation
can be explained in the light of the crystal structure of
the JMJD2A double Tudor domain in complex with the
H4K20me3 peptide (pdb entry 2QQS) [18] (Figure 7).
T h ed o u b l eT u d o rd o m a i na m i n oa c i ds i d ec h a i n so f
D939 and F937 are in close proximity to the unmodified
arginine 19 of the H4 peptide. On the basis of this, we
speculate that the so far hypothetical methylation of
arginine 19 would interfere sterically with the position-
ing of D939 and/or F937, which may explain the
reduced binding of the double Tudor domain of
H4K20me3/H4R19me2a/s double modified peptides
observed on the peptide array.
As described, with the JMJD2A double Tudor domain,
we observed combined readout of H3K4me3 and
H3K9me3 which is interesting, because both marks have
opposing biological effects. Since JMJD2A is known to
demethylate H3K9me3 [44,45], one could speculate that
H3K4me3/K9me3 dual modified chromatin is an inter-
mediate in the reactivation of H3K9me3 silenced chro-
matin, where trimethylation of K4 would recruit the
JMJD2A activity that would finalize the switch from
H3K9me3 repressed to H3K4me3 active chromatin.
Interestingly, the ATRX ADD domain performs a
combined readout of H3K4 and K9 as well, but in this
case the preferred combination is H3K4me0 and
H3K9me3, which is both characteristic of transcription-
ally inactive chromatin.
Conclusions
We describe the application of Celluspots peptide arrays
which contain 384 histone peptides carrying 59 post-
translational modifications in different combinations as
an inexpensive, reliable and fast method for initial
screening for specific interactions of reading domains
with modified histone peptides. Since peptide arrays are
screening tools, unexpected or novel results need to be
confirmed by equilibrium peptide binding experiments
using purified peptides. In our experience, such studies
often confirmed results from peptide arrays. For exam-
ple in the case of the Dnmt3a PWWP domain, binding
to H3K36me3 on the peptide array could be verified by
peptide binding, pull-down of native nucleosomes and
functional DNA methylation experiments [19]. Similarly,
the initial observation of a combinatorial readout of
H3K9me3 when H3K4 is not di- or trimethylated by the
ATRX ADD domain on the peptide array was confirmed
by chromatin pull-down and peptide binding assays in
our laboratory [40] and later also by others [42,43]. The
same is true for the Dnmt3a ADD domain recognition
of unmodified H3K4, which is important for the methy-
lation of DNA by Dnmt3a, where peptide array results
[31] nicely agreed with published equilibrium peptide
binding data [41]. Here, we confirmed by peptide bind-
ing that MPP8 Chromo domain binding to H3K9me3 is
inhibited by S10ph. In all these cases, the initial peptide
array results prompted further experiments, which con-
firmed them and in some cases it was possible to show
a biological relevance. We conclude that Celluspots pep-
tide arrays are well suited tools to study the PTM speci-
fic interactions of reading domains and reading domain
variants with modified histone tails.
Methods
Cloning, expression and purification of reading domains
The sequences encoding human HP1ß full length (resi-
dues 1-185), the Chromo domain of human MPP8 (resi-
dues 58-112), the double Tudor domain of human
JMJD2A (residues 856-1047), the tandem Tudor domain
of human 53BP1 (residues 1490-1608), the PHD finger
of human Rag2 (residues 311-520) and the second
Bromo domain of human BRD2 (residues 348-455) were
amplified from cDNA derived from HEK293 cells and
cloned as GST fusion proteins into the pGEX-6P-2 vec-
tor (GE Healthcare). The sequence encoding the PWWP
domain of murine Dnmt3a (residues 279-420) was sub-
cloned as GST-fusion protein into the pGEX-6P-2 vec-
tor (GE Healthcare). The GST-tagged proteins were
Figure 7 Interaction between JMJD2A double Tudor domain
and R19 in H4K20me3 peptide. The backbone of JMJD2A double
Tudor domain (pdb entry 2QQS) is shown in orange. Amino acid
side chains of the Tudor domains either interacting with H4K20me3
or H4R19 are shown in red. The H4-peptide backbone is shown in a
medium blue with the side chains of K20me3 and R19 highlighted
in a dark blue. The side chains of F932, D934, Y973 and W967 form
an aromatic cage around the trimethylated lysine 20, while the side
chains of F937 and D939 interact with unmodified R19. The
distances of the side chains atoms of D939 and F937 to R19 are
indicated.
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tein concentration was determined by UV spectroscopy.
Site directed mutagenesis was performed as described
[40].
Peptide arrays
Celluspots peptide arrays spotted on glass slides were pro-
vided from Intavis AG (Köln, Germany). They are now
commercially available from Active Motif (Cat. No. 13001).
The peptide sequences and PTMs are specified in the
Additional File 1. For quality control, each glass slide con-
tains two copies of the array. We have shown previously
that antibody binding to these internal duplicates was
highly reproducible which ensures reproducible peptide
spotting [21]. Similar results were observed here with read-
ing domains. By mass spectrometric analysis, we showed
previously that the peptide spots contained the full length
product and sometimes some shorter by-products as well
[21] which is expected, since unpurified peptides are used.
These heterogeneous contaminating peptides did not affect
antibody binding in a detectable manner, because the
arrays present much more peptides than available surface
binding sites for antibodies or reading domain. Antibody
binding to arrays prepared from independent peptide
synthesis was highly reproducible [21].
Binding of protein domains to peptide arrays
The array was blocked by incubation in TTBS buffer (10
mM Tris/HCl pH 7.5, 0.05% Tween-20 and 150 mM
NaCl) containing 5% non-fat dried milk at 4°C over-
night, then washed two times with TTBS buffer, one
time with interaction buffer (100 mM KCl, 20 mM
H E P E Sp H7 . 5 ,1m ME D T A ,0 . 1m MD T Ta n d1 0 %
glycerol), and incubated with purified GST-tagged read-
ing domains: HP1ß full length protein (10 nM), MPP8
Chromo domain (0.5 μM), JMJD2A double Tudor
domains (10 nM), 53BP1 tandem Tudor domain (1 μM),
Dnmt3a PWWP domain (50 nM), Rag2 PHD finger (2
nM) and BRD2 Bromo domain 2 (10 nM) at room tem-
perature for 2 hours in interaction buffer. After washing
with TTBS buffer three times, the array was incubated
with goat anti-GST antibody (GE Healthcare #27- 4577-
01) 1:5000 dilution in TTBS buffer containing 1% non-
f a td r i e dm i l kf o r1ha tr o o mt e m p e r a t u r e .T h e n ,t h e
membrane was washed three times with TTBS and
incubated with horseradish peroxidase conjugated anti-
goat antibody (Invitrogen #81-1620) 1:12000 in TTBS
containing 1% non-fat dried milk for 1 h at room tem-
perature. Finally, the membrane was washed four times
with TTBS and submerged in ECL developing solution
(Thermo Fisher Scientific) and image was captured on
an X-ray film. Typical exposure times were 0.5-5 min.
Analysis was done using the Array Analyze program,
which was also used to prepare the graphs shown in
F i g u r e s1 ,5a n d6 .T h ep r o g r a mr u n su n d e rM S - W i n -
dows and it is available free of charge at http://www.
activemotif.com/catalog/667.html or from the authors
upon request.
Peptide binding experiments
Peptide binding of the MPP8 Chromo domain was ana-
lyzed by fluorescence depolarization using a Varian
Carry Eclipse fluorescence spectrophotometer as
described [40]. Purified FITC-coupled peptides
(H3K9me3 and H3K9me3-S10ph, both amino acids 1-
19) were purchased from Intavis AG (Köln, Germany).
Additional material
Additional file 1: Supplemental information S1.xls. Compilation of
the peptides presented on the Celluspots arrays. Excel file showing the
Figure 8 Coomassie stained SDS gel showing the purified proteins used for peptide binding experiments. Loading was not adjusted to
protein concentrations. The purification of the Dnmt3a PWWP domain is shown in Dhayalan et al. (2010) [19].
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Page 10 of 12sequences, modifications and positions of all peptides on the Celluspots
arrays.
Acknowledgements
This work was supported by the BMBF grant 0315886B. Thanks are due to
Intavis AG (Köln, Germany) for providing materials.
Author details
1Biochemistry Laboratory, School of Engineering and Science, Jacobs
University Bremen, Campus Ring 1, 28759 Bremen, Germany.
2Department of
Biotechnology, Pondicherry University, R.V. Nagar, Kalapet, Puducherry -
605014, India.
Authors’ contributions
IB, AD, SK, GK and RT conducted and analyzed the experiments. IB, AD and
AJ designed the study. IB and AJ were involved in data analysis and
interpretation and drafted the manuscript. All authors read and approved
the final manuscript.
Received: 14 June 2011 Accepted: 31 August 2011
Published: 31 August 2011
References
1. Kouzarides T: Chromatin modifications and their function. Cell 2007,
128(4):693-705.
2. Lee JS, Smith E, Shilatifard A: The language of histone crosstalk. Cell 2010,
142(5):682-685.
3. Berger SL: The complex language of chromatin regulation during
transcription. Nature 2007, 447(7143):407-412.
4. Sims RJ, Reinberg D: Is there a code embedded in proteins that is based
on post-translational modifications? Nat Rev Mol Cell Biol 2008,
9(10):815-820.
5. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ: How chromatin-
binding modules interpret histone modifications: lessons from
professional pocket pickers. Nat Struct Mol Biol 2007, 14(11):1025-1040.
6. Yun M, Wu J, Workman JL, Li B: Readers of histone modifications. Cell Res
2011, 21(4):564-578.
7. Kanno T, Kanno Y, Siegel RM, Jang MK, Lenardo MJ, Ozato K: Selective
recognition of acetylated histones by bromodomain proteins visualized
in living cells. Mol Cell 2004, 13(1):33-43.
8. Lachner M, O’Carroll D, Rea S, Mechtler K, Jenuwein T: Methylation of
histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001,
410(6824):116-120.
9. Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC,
Kouzarides T: Selective recognition of methylated lysine 9 on histone H3
by the HP1 chromo domain. Nature 2001, 410(6824):120-124.
10. Bua DJ, Kuo AJ, Cheung P, Liu CL, Migliori V, Espejo A, Casadio F, Bassi C,
Amati B, Bedford MT, Guccione E, Gozani O: Epigenome microarray
platform for proteome-wide dissection of chromatin-signaling networks.
PLoS One 2009, 4(8):e6789.
11. Quinn AM, Bedford MT, Espejo A, Spannhoff A, Austin CP, Oppermann U,
Simeonov A: A homogeneous method for investigation of methylation-
dependent protein-protein interactions in epigenetics. Nucleic Acids Res
2010, 38(2):e11.
12. Kokura K, Sun L, Bedford MT, Fang J: Methyl-H3K9-binding protein MPP8
mediates E-cadherin gene silencing and promotes tumour cell motility
and invasion. EMBO J 2010, 29(21):3673-3687.
13. Chang Y, Horton JR, Bedford MT, Zhang X, Cheng X: Structural Insights for
MPP8 Chromodomain Interaction with Histone H3 Lysine 9: Potential
Effect of Phosphorylation on Methyl-Lysine Binding. J Mol Biol 2011,
408(5):807-814.
14. Kim J, Daniel J, Espejo A, Lake A, Krishna M, Xia L, Zhang Y, Bedford MT:
Tudor, MBT and chromo domains gauge the degree of lysine
methylation. EMBO Rep 2006, 7(4):397-403.
15. Botuyan MV, Lee J, Ward IM, Kim JE, Thompson JR, Chen J, Mer G:
Structural basis for the methylation state-specific recognition of histone
H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 2006, 127(7):1361-1373.
16. Huyen Y, Zgheib O, Ditullio RA Jr, Gorgoulis VG, Zacharatos P, Petty TJ,
Sheston EA, Mellert HS, Stavridi ES, Halazonetis TD: Methylated lysine 79 of
histone H3 targets 53BP1 to DNA double-strand breaks. Nature 2004,
432(7015):406-411.
17. Huang Y, Fang J, Bedford MT, Zhang Y, Xu RM: Recognition of histone H3
lysine-4 methylation by the double tudor domain of JMJD2A. Science
2006, 312(5774):748-751.
18. Lee J, Thompson JR, Botuyan MV, Mer G: Distinct binding modes specify
the recognition of methylated histones H3K4 and H4K20 by JMJD2A-
tudor. Nat Struct Mol Biol 2008, 15(1):109-111.
19. Dhayalan A, Rajavelu A, Rathert P, Tamas R, Jurkowska RZ, Ragozin S,
Jeltsch A: The Dnmt3a PWWP domain reads histone 3 lysine 36
trimethylation and guides DNA methylation. J Biol Chem 2010,
285(34):26114-26120.
20. Matthews AG, Kuo AJ, Ramon-Maiques S, Han S, Champagne KS, Ivanov D,
Gallardo M, Carney D, Cheung P, Ciccone DN, Walter KL, Utz PJ, Shi Y,
Kutateladze TG, Yang W, Gozani O, Oettinger MA: RAG2 PHD finger
couples histone H3 lysine 4 trimethylation with V(D)J recombination.
Nature 2007, 450(7172):1106-1110.
21. Bock I, Dhayalan A, Kudithipudi S, Brandt O, Rathert P, Jeltsch A: Detailed
specificity analysis of antibodies binding to modified histone tails with
peptide arrays. Epigenetics 2011, 6(2):256-263.
22. Frank R: The SPOT-synthesis technique. Synthetic peptide arrays on
membrane supports–principles and applications. J Immunol Methods
2002, 267(1):13-26.
23. Hilpert K, Winkler DF, Hancock RE: Peptide arrays on cellulose support:
SPOT synthesis, a time and cost efficient method for synthesis of large
numbers of peptides in a parallel and addressable fashion. Nature
protocols 2007, 2(6):1333-1349.
24. Tegge WJ, Frank R: Analysis of protein kinase substrate specificity by the
use of peptide libraries on cellulose paper (SPOT-method). Methods Mol
Biol 1998, 87:99-106.
25. Hilpert K, Hansen G, Wessner H, Schneider-Mergener J, Hohne W:
Characterizing and optimizing protease/peptide inhibitor interactions, a
new application for spot synthesis. J Biochem (Tokyo) 2000,
128(6):1051-1057.
26. Panse S, Dong L, Burian A, Carus R, Schutkowski M, Reimer U, Schneider-
Mergener J: Profiling of generic anti-phosphopeptide antibodies and
kinases with peptide microarrays using radioactive and fluorescence-
based assays. Molecular diversity 2004, 8(3):291-299.
27. Rathert P, Zhang X, Freund C, Cheng X, Jeltsch A: Analysis of the substrate
specificity of the Dim-5 histone lysine methyltransferase using peptide
arrays. Chem Biol 2008, 15(1):5-11.
28. Rathert P, Dhayalan A, Murakami M, Zhang X, Tamas R, Jurkowska R,
Komatsu Y, Shinkai Y, Cheng X, Jeltsch A: Protein lysine methyltransferase
G9a acts on non-histone targets. Nat Chem Biol 2008, 4(6):344-346.
29. Reineke U, Sabat R: Antibody epitope mapping using SPOT peptide
arrays. Methods Mol Biol 2009, 524:145-167.
30. Wu C, Li SS: CelluSpots: a reproducible means of making peptide arrays
for the determination of SH2 domain binding specificity. Methods Mol
Biol 2009, 570:197-202.
31. Zhang Y, Jurkowska R, Soeroes S, Rajavelu A, Dhayalan A, Bock I, Rathert P,
Brandt O, Reinhardt R, Fischle W, Jeltsch A: Chromatin methylation activity
of Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain
with the histone H3 tail. Nucleic Acids Res 2010, 38(13):4246-4253.
32. Dhayalan A, Kudithipudi S, Rathert P, Jeltsch A: Specificity analysis-based
identification of new methylation targets of the SET7/9 protein lysine
methyltransferase. Chem Biol 2011, 18(1):111-120.
33. Winkler DF, Hilpert K, Brandt O, Hancock RE: Synthesis of peptide arrays
using SPOT-technology and the CelluSpots-method. Methods Mol Biol
2009, 570:157-174.
34. Fischle W, Tseng BS, Dormann HL, Ueberheide BM, Garcia BA,
Shabanowitz J, Hunt DF, Funabiki H, Allis CD: Regulation of HP1-chromatin
binding by histone H3 methylation and phosphorylation. Nature 2005,
438(7071):1116-1122.
35. Jacobs SA, Khorasanizadeh S: Structure of HP1 chromodomain bound to a
lysine 9-methylated histone H3 tail. Science 2002, 295(5562):2080-2083.
36. LeRoy G, Rickards B, Flint SJ: The double bromodomain proteins Brd2 and
Brd3 couple histone acetylation to transcription. Mol Cell 2008,
30(1):51-60.
Bock et al. BMC Biochemistry 2011, 12:48
http://www.biomedcentral.com/1471-2091/12/48
Page 11 of 1237. Umehara T, Nakamura Y, Wakamori M, Ozato K, Yokoyama S,
Padmanabhan B: Structural implications for K5/K12-di-acetylated histone
H4 recognition by the second bromodomain of BRD2. FEBS letters 2010,
584(18):3901-3908.
38. Moriniere J, Rousseaux S, Steuerwald U, Soler-Lopez M, Curtet S, Vitte AL,
Govin J, Gaucher J, Sadoul K, Hart DJ, Krijgsveld J, Khochbin S, Muller CW,
Petosa C: Cooperative binding of two acetylation marks on a histone tail
by a single bromodomain. Nature 2009, 461(7264):664-668.
39. Liu H, Galka M, Iberg A, Wang Z, Li L, Voss C, Jiang X, Lajoie G, Huang Z,
Bedford MT, Li SS: Systematic identification of methyllysine-driven
interactions for histone and nonhistone targets. J Proteome Res 2010,
9(11):5827-5836.
40. Dhayalan A, Tamas R, Bock I, Tattermusch A, Dimitrova E, Kudithipudi S,
Ragozin S, Jeltsch A: The ATRX-ADD domain binds to H3 tail peptides
and reads the combined methylation state of K4 and K9. Hum Mol Genet
2011, 20(11):2195-2203.
41. Otani J, Nankumo T, Arita K, Inamoto S, Ariyoshi M, Shirakawa M: Structural
basis for recognition of H3K4 methylation status by the DNA
methyltransferase 3A ATRX-DNMT3-DNMT3L domain. EMBO Rep 2009,
10(11):1235-1241.
42. Iwase S, Xiang B, Ghosh S, Ren T, Lewis PW, Cochrane JC, Allis CD,
Picketts DJ, Patel DJ, Li H, Shi Y: ATRX ADD domain links an atypical
histone methylation recognition mechanism to human mental-
retardation syndrome. Nat Struct Mol Biol 2011, 18(7):769-776.
43. Eustermann S, Yang JC, Law MJ, Amos R, Chapman LM, Jelinska C,
Garrick D, Clynes D, Gibbons RJ, Rhodes D, Higgs DR, Neuhaus D:
Combinatorial readout of histone H3 modifications specifies localization
of ATRX to heterochromatin. Nat Struct Mol Biol 2011, 18(7):777-782.
44. Ng SS, Kavanagh KL, McDonough MA, Butler D, Pilka ES, Lienard BM,
Bray JE, Savitsky P, Gileadi O, von Delft F, Rose NR, Offer J, Scheinost JC,
Borowski T, Sundstrom M, Schofield CJ, Oppermann U: Crystal structures of
histone demethylase JMJD2A reveal basis for substrate specificity. Nature
2007, 448(7149):87-91.
45. Couture JF, Collazo E, Ortiz-Tello PA, Brunzelle JS, Trievel RC: Specificity and
mechanism of JMJD2A, a trimethyllysine-specific histone demethylase.
Nat Struct Mol Biol 2007, 14(8):689-695.
doi:10.1186/1471-2091-12-48
Cite this article as: Bock et al.: Application of Celluspots peptide arrays
for the analysis of the binding specificity of epigenetic reading domains
to modified histone tails. BMC Biochemistry 2011 12:48.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bock et al. BMC Biochemistry 2011, 12:48
http://www.biomedcentral.com/1471-2091/12/48
Page 12 of 12